Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia

Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures. Here, we investigate the effect of risedronate on BMD after 5 years of follow-up i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sestak, Ivana, Blake, Glen M., Patel, Rajesh, Coleman, Robert E., Cuzick, Jack, Eastell, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548284/
https://www.ncbi.nlm.nih.gov/pubmed/31028957
http://dx.doi.org/10.1016/j.bone.2019.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548284/
https://www.ncbi.nlm.nih.gov/pubmed/31028957
http://dx.doi.org/10.1016/j.bone.2019.04.016

Ejemplares similares